Send me a question or story!

Janus kinase (JAK) inhibitors have become a cornerstone in managing pruritic and allergic skin disease in dogs by targeting the JAK-STAT signaling pathway, which transmits itch and inflammatory cytokine signals. With so many medications hitting the market, it is important to understand the differences between all of the different JAK inhibitors in veterinary medicine.

Apoquel (oclacitinib) has been in the veterinary field the longest with over a decade of use. However, Zenrelia (ilunocitinib) has been available in many countries for over a year. Additionally, Numelvi (atinvicitinib) has recently become available in Europe and will hit the market in the United States very soon (with others to follow). 

Learn about the differences in these medications and why it is important to become comfortable with all of them on this week's episode of The Derm Vet podcast.

Timestamps
00:00 Intro
01:35 JAK Inhibitor Basics
02:35 What are JAK Receptors
03:31 Apoquel and Zenrelia 
05:20 Numelvi 
07:57 How To Tell If a Pet Is Atopic 
09:12 Are JAK Inhibitors Safe with Neoplasia
11:32 What Does JAK Selectivity Mean 
13:47 Common Side-Effects of JAK Inhibitors 
17:01 Using JAK Inhibitors Off-Label
18:51 Outro